Abstract
Immunosuppressive treatment still is an important element in the management of autoimmune mediated diseases. However, immunosuppressive therapy is often complicated by a narrow therapeutic index and high variability of treatment response. This review discusses the clinical management and monitoring strategies for the use of ciclosporin A, tacrolimus, azathioprine, mycophenolat mofetil, mitoxantrone and some monoclonal antibodies with focus on natalizumab.
Keywords: Neuroimmunology, therapeutic drug monitoring, mitoxantrone, natalizumab, ciclosporin A, azathioprine, mycophenolat mofetil, immunosuppressive therapy, tacrolimus, monoclonal antibodies.
Current Pharmaceutical Design
Title:Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Volume: 18 Issue: 29
Author(s): Nicolas von Ahsen and Andrew Chan
Affiliation:
Keywords: Neuroimmunology, therapeutic drug monitoring, mitoxantrone, natalizumab, ciclosporin A, azathioprine, mycophenolat mofetil, immunosuppressive therapy, tacrolimus, monoclonal antibodies.
Abstract: Immunosuppressive treatment still is an important element in the management of autoimmune mediated diseases. However, immunosuppressive therapy is often complicated by a narrow therapeutic index and high variability of treatment response. This review discusses the clinical management and monitoring strategies for the use of ciclosporin A, tacrolimus, azathioprine, mycophenolat mofetil, mitoxantrone and some monoclonal antibodies with focus on natalizumab.
Export Options
About this article
Cite this article as:
von Ahsen Nicolas and Chan Andrew, Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases, Current Pharmaceutical Design 2012; 18(29) . https://dx.doi.org/10.2174/138161212802502152
DOI https://dx.doi.org/10.2174/138161212802502152 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Gut Inflammation: Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities
Current Pharmaceutical Design CXXC5 Associates with Smads to Mediate TNF-α Induced Apoptosis
Current Molecular Medicine Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued) Migraine in Systemic Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Hot topic: Editorial [Therapeutic Potential of Peptide Motifs - Part IV] (Jean Claude Herve)
Current Pharmaceutical Design B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews Mucosal Immunity - Basic Principles, Ontogeny, Cystic Fibrosis and Mucosal Vaccination
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Animal Models of Central Nervous System Immune-Mediated Diseases: Therapeutic Interventions with Bioactive Peptides and Mimetics
Current Medicinal Chemistry Natural Tregs in Systemic Lupus Erythematosus
Current Immunology Reviews (Discontinued) IL-27: Friend or Foe in the Autoimmune Diseases
Current Immunology Reviews (Discontinued) Identification of Moesin as a Novel Autoantigen in Patients with Sjögren’s Syndrome
Protein & Peptide Letters Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
Current Pharmaceutical Design Therapeutic Strategies in Autoimmune Diseases by Interfering with Leukocyte Endothelium Interaction
Current Pharmaceutical Design Serum Procalcitonin Levels in Febrile Patients with Systemic Autoimmune Diseases
Current Rheumatology Reviews Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
Current Rheumatology Reviews Use of Liposomal Drugs in the Treatment of Rheumatoid Arthritis
Current Rheumatology Reviews Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued)